Form 4: Syndax Director Pierre Legault Receives RSU Award

Syndax Pharmaceuticals director Pierre Legault was granted 24,000 Restricted Stock Units, aligning his interests with shareholders.

Summary

• Pierre Legault, a Director of Syndax Pharmaceuticals Inc. (SNDX), was granted 24,000 shares of Common Stock.
• This transaction occurred on February 4, 2026, at a price of $0 per share, indicating an award of Restricted Stock Units (RSUs).
• Following this award, Mr. Legault beneficially owns 114,000 shares of Syndax Pharmaceuticals Common Stock.
• The RSUs vest one year from the grant date, and the underlying shares are restricted from delivery, transfer, or sale until separation from service, death, disability, or a change in control.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, reflecting standard director compensation practices and aligning insider interests with shareholders, without indicating any significant operational or financial changes.

Positives

• The award of 24,000 Restricted Stock Units to Director Pierre Legault aligns his long-term interests with those of shareholders.
• Equity-based compensation is a common practice to incentivize directors and retain talent.

Negatives

• No negative aspects are directly indicated in this routine insider transaction filing.

Risks

• No specific risks are mentioned in this Form 4 filing, which primarily reports a change in beneficial ownership.

Future Outlook

The filing does not contain forward-looking statements or guidance regarding the company's future performance. It only details a past transaction.

Industry Context

StockSavvy.ai notes that equity awards, such as Restricted Stock Units, are a standard component of director compensation packages across the biotechnology and pharmaceutical industries. This practice aims to align the interests of board members with the long-term performance of the company and its shareholders, a common strategy seen in peers like Gilead Sciences or Amgen.

Comparison to Industry Standards

• The grant of 24,000 Restricted Stock Units to a director is consistent with typical non-employee director compensation structures in the biopharmaceutical sector, which often include a mix of cash retainers and equity awards.
• For example, similar RSU grants are observed at companies like BioNTech SE or Moderna Inc., where director equity compensation often ranges from tens of thousands to over a hundred thousand dollars in value annually, depending on company size and performance.

Related Party Transactions

• This RSU award to Director Pierre Legault constitutes a related party transaction, as it involves compensation from the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The award aligns the director's interests with long-term shareholder value.
• Employees: No direct impact on general employees is indicated.
• Management: Reinforces the compensation structure for board members.

Next Steps

• The 24,000 Restricted Stock Units will vest one year from the grant date (February 4, 2026).
• The underlying shares will be delivered upon the earlier of separation from service, death, disability, or a change in control.

Key Dates

Recommendation

This Form 4 filing reports a routine equity award to a director and does not contain information significant enough to warrant a change in investment recommendation. It's a standard compensation event that aligns director interests with shareholders, but it doesn't provide new insights into the company's operational performance or strategic direction that would drive a 'buy' or 'sell' decision. Therefore, a 'hold' recommendation is appropriate, maintaining current positions while awaiting more substantive company updates.

Keywords

Syndax Pharmaceuticals, SNDX, Pierre Legault, Form 4, Restricted Stock Units, RSU, Insider Transaction, Director Compensation, Equity Award